Lopinavir ritonavir
Sponsors
Göteborg University, Dr Birgit Whitman, Cytel Inc, Inserm ANRS, DNDi
Conditions
COVID-19Covid-19HIV
Phase 2
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial (INTENSE-COV)
Active, not recruitingPACTR202007720062393
Start: 2020-07-20Target: 294Updated: 2026-09-14
An Adaptive Randomized Platform Trial to Investigate the Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults.
Active, not recruitingPACTR202007700757139
Start: 2020-07-13Target: 420Updated: 2026-09-14
Phase 3
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
Active, not recruitingPACTR202004893013257
Start: 2020-04-25Target: 6400Updated: 2026-09-14
The impact of COVID-19 treatment on the type, strength and duration of antibody and cellular immune responses in SARS-CoV-2 patients in sub-Saharan Africa
Ancillary Study of the ANTICOV Study:
An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19
Active, not recruitingPACTR202010781639956
Start: 2020-09-21Target: 1000Updated: 2026-09-14
Factors affecting transmission of SARS-CoV-2 in Households of SARS-CoV-2 patients in Sub-Saharan Africa Ancillary study of the ANTICOV Study: An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19
Active, not recruitingPACTR202010718451278
Start: 2020-11-02Target: 1500Updated: 2026-09-14